Financial statement 2007

Record sales in fourth quarter

January - December 2007
• Net sales rose by 32% to SEK 76.4m (58.1)
• The number of tests sold rose by 64% and amounted to 750,500 (459,000)
• The number of repeat tests sold rose by 125%
• The gross margin was 67% (63)
• The loss after tax amounted to SEK 113.9m (88.4)
• The loss per share before dilution amounted to SEK 2.7 (2.5

Comment by the CEO
“Sales of tests conducted with Aerocrine’s products demonstrate a continued favourable trend in the company’s existing markets. With the purpose of broadening the commercial base, several key steps have been taken to introduce Aerocrine’s main product to larger markets. The company has signed distribution agreements in China, Japan and France, and has strengthened its management and commercial organisation in the US” says Paul de Potocki, Aerocrine’s CEO.

For further information, please contact:
Paul de Potocki, CEO Phone: +46 8 629 07 82
Michael Colérus, CFO Phone +46 8 629 07 85